Press releasePRNewswire
Pacira Biosciences
PCRX · NASDAQ
$36.38+$0.04 (+0.11%)TodayMarket closed ·
Prev close $36.34
Latest news
- Press releaseBusiness Wire
Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRX
- Press releasePRNewswire
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Pacira BioSciences, Inc. (NASDAQ: PCRX)
- NewsAvi Kapoor
Nasdaq Falls Over 300 Points as Oil Prices Surge: Investor Sentiment Weakens, Fear & Greed Index Remains in ‘Fear’ Zone
- NewsVandana Singh
Viatris Bets Big on Non-Opioid Painkillers With Pacira Buyout
- Press releasePRNewswire
PCRX SHAREHOLDER ALERT: ADEMI LLP INVESTIGATES WHETHER BUYOUT FAIRLY VALUES PACIRA BIOSCIENCES, INC.
- NewsAvi Kapoor
Crude Oil Gains 5%; PepsiCo Posts Upbeat Q3 Earnings
- NewsAvi Kapoor
Helen Of Troy Posts Upbeat Q2 Earnings, Joins Pacira Biosciences, Wolfspeed And Other Big Stocks Moving Higher On Thursday
- Press releaseBusiness Wire
PCRX Stock Alert: Halper Sadeh LLC is Investigating Whether Pacira BioSciences, Inc. is Obtaining a Fair Price for its Shareholders
- Press releasePRNewswire
Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies
- Press releaseGlobe Newswire
Pacira Announces Exclusive Agreement with Molteni Farmaceutici to Commercialize EXPAREL® in the European Union and United Kingdom
- Press releaseGlobe Newswire
Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases
- News
Pacira BioSciences Q2 Adj. EPS $0.73 Beats $0.65 Estimate, Sales $192.400M Beat $190.816M Estimate
- Press releaseGlobe Newswire
Pacira BioSciences Reports Second Quarter 2026 Financial Results
- Press releaseGlobe Newswire
Pacira BioSciences Advances PCRX-201 Development Program with Successful Transition to Scalable Commercial Manufacturing Process
- News
Pacira BioSciences Divests Iovera To Zimmer Biomet For Up To $140M
- Press releaseGlobe Newswire
Pacira BioSciences Announces Agreement to Divest its iovera° Business to Zimmer Biomet
- Press releasePRNewswire
Pacira BioSciences Announces Stockholders Have Elected All Three of the Company's Director Nominees at Annual Meeting
- Press releasePRNewswire
Pacira BioSciences Reminds Stockholders to Vote the BLUE Proxy Card "FOR" the Election of the Company's Highly Qualified Nominees Ahead of its Annual Meeting
- Press releasePRNewswire
Pacira BioSciences Highlights Leading Independent Proxy Advisory Firm ISS' Recommendation to Vote "FOR" All of Pacira's Director Nominees
- Press releasePRNewswire
DOMA PERPETUAL CAPITAL MANAGEMENT QUESTIONS WHY SHAREHOLDERS SHOULD VOTE TO CONTINUE WITH A BOARD THAT HAS OVERSEEN A DECADE OF VALUE DESTRUCTION
- Press releaseGlobe Newswire
Pacira BioSciences Mails Letter to Stockholders Reiterating Confidence in the Company's Strategic Direction and Highly Qualified Nominees
- Press releaseGlobe Newswire
After Fifty Years of Implants, a Newly Public Biotech Is Trying to Rebuild the Breast Instead
- Press releaseGlobe Newswire
A Reno Biotech Just Rang the Nasdaq Bell — Here's Why the Whole Regenerative-Medicine Tape Is Worth Watching
- Press releasePRNewswire
A LETTER TO PACIRA BIOSCIENCES SHAREHOLDERS FROM DOMA PERPETUAL CAPITAL MANAGEMENT LLC
- Press releasePRNewswire
DOMA Perpetual Director Nominees Send Letter to Shareholders of Pacira Biosciences
- Press releasePRNewswire
DOMA Perpetual Issues & Mails Letter to Shareholders of Pacira BioSciences - Along with its Definitive Proxy Statement & WHITE Proxy Card - Urging Shareholders to Vote "FOR" DOMA's Three Highly Qualified, Independent Board Candidates
- News
Pacira BioSciences Q1 2026 Earnings Call Transcript
- Press releasePRNewswire
DOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences, Inc.
- NewsAvi Kapoor
Crude Oil Rises Sharply; US Consumer Sentiment Edges Higher In January
- News
What Analysts Are Saying About Pacira BioSciences Stock
- Press releasePRNewswire
DOMA Perpetual Capital Management Announces Intent to Nominate Three Highly Qualified, Independent Director Candidates at 2026 Annual Meeting of Pacira BioSciences, Inc.
- Press releasePRNewswire
DOMA Perpetual Sends Letter Calling for the Board of Directors of Pacira BioSciences, Inc. to Immediately Explore a Sale of the Business
- News
Earnings Scheduled For November 6, 2025
- News
Earnings Scheduled For August 5, 2025
- Press releasePRNewswire
Investors who lost money with shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) should contact the Shareholders Foundation in connection with Lawsuit
- Press releaseGlobe Newswire
PACIRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Pacira BioSciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
- Press releasePRNewswire
Lawsuit for Investors in shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) announced by the Shareholders Foundation
- News
Where Pacira BioSciences Stands With Analysts
- News
Earnings Scheduled For May 8, 2025
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.